Now Available

HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.1

 

HEPLISAV-B recommended by CDC Advisory Committee on Immunization Practices (ACIP) for the Prevention of Hepatitis B in Adults.2 

icon_doses.pngicon_month.png

The First and Only 2-Dose Hepatitis B Vaccine for Adults ≥ 18 Years

Administer HEPLISAV-B by intramuscular injection in the deltoid region using a sterile needle and syringe.

 

INDICATION
HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

IMPORTANT SAFETY INFORMATION
Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (eg, anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.

Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).

Visit www.HEPLISAV-B.com for more information.